SCHEDULE: Millennium Entities Disclose 6.3% Stake in AN2 Therapeutics

Millennium Management LLC and affiliated entities have reported a collective beneficial ownership of 6.3% in AN2 Therapeutics, Inc. common stock.

Summary

• Integrated Core Strategies (US) LLC beneficially owns 2,135,044 shares, representing 6.0% of AN2 Therapeutics, Inc. common stock.
• Millennium Management LLC, Millennium Group Management LLC, and Israel A. Englander each beneficially own 2,237,102 shares, representing 6.3% of AN2 Therapeutics, Inc. common stock.
• The ownership percentages are calculated based on 35,647,635 shares of Common Stock outstanding, which includes 8,245,611 shares issued in a private placement around March 10, 2026.
• The reporting persons have shared voting and dispositive power over their respective beneficially owned shares.
• The filing certifies that the securities were not acquired for the purpose of changing or influencing control of the issuer.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive development, as a significant stake by a prominent institutional investor like Millennium Management can be interpreted as a vote of confidence in AN2 Therapeutics, especially following a recent private placement.

Positives

• Significant institutional investment from Millennium Management and its affiliates indicates confidence in AN2 Therapeutics.
• The disclosure follows a recent private placement, suggesting these entities participated or increased their stake post-placement.

Future Outlook

Not applicable, as this filing is a disclosure of beneficial ownership and does not contain forward-looking statements or guidance from the issuer.

Industry Context

StockSavvy.ai notes that significant institutional ownership by firms like Millennium Management can often signal increased investor interest and potential validation of a company's long-term prospects within the biotechnology sector. Such disclosures are closely watched by the market for insights into institutional sentiment.

Stakeholder Impact

• Shareholders: Increased institutional ownership may lead to greater market confidence and potentially influence stock price stability or upward movement.
• Company Management: A significant institutional stake could lead to increased scrutiny or engagement from the investor, potentially influencing strategic decisions.

Key Dates

Recommendation

The disclosure of a significant institutional stake by Millennium Management is generally a positive signal, indicating investor confidence. However, a Schedule 13G filing primarily reports ownership and does not provide new operational or financial performance data to warrant a 'buy' or 'sell' recommendation. Investors should 'hold' and monitor future company performance and additional disclosures for more comprehensive investment decisions.

Keywords

AN2 Therapeutics, Millennium Management, Integrated Core Strategies, Israel A. Englander, Beneficial Ownership, Schedule 13G, Common Stock, Institutional Investor, Equity Stake, Biotechnology